tumor necrosis factor-alpha

(redirected from Tumor necrosis factor alpha)
Also found in: Acronyms, Wikipedia.

tumor necrosis factor-α

a pleiotropic cytokine synthesized widely throughout the female reproductive tract.
References in periodicals archive ?
While the mice that overexpressed only tumor necrosis factor alpha quickly developed arthritis along with significant bone and weight loss, those that also overexpressed GILZ had significantly less bone loss, Shi said.
Scope - DelveInsight's report provides a Tumor Necrosis Factor Alpha (TNF-a) Agonists Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Tumor Necrosis Factor Alpha (TNF-a) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Tumor Necrosis Factor Alpha (TNF-a) Agonists and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery.
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.
Anchorage-independent transformation has been observed in clone 41 cells treated with TPA, epidermal growth factor (EGF), tumor necrosis factor alpha (TNF[alpha]) (5), and other tumor promoters (6).
The drug, sold commercially as Remicade, is a monoclonal antibody that attacks a protein that's made by immune cells called tumor necrosis factor alpha (TNF-alpha).
today announced that it has licensed rights for all gene therapy applications of the tumor necrosis factor alpha (TNF alpha) gene in the United States from Asahi Chemical Industry Co.
Some research points instead to a compound called tumor necrosis factor alpha as a trigger for insulin resistance, Flier says.
Other on-going trials with Synovir are investigating its utility in treating severe rheumatoid arthritis, cachexia in cancer patients, HIV replication, and modulating levels of tumor necrosis factor alpha (TNF alpha) in AIDS patients undergoing Interleukin-2 (IL-2) therapy for potential immune restoration.
In that time, concentrations of the AGE-linked cholesterol and the inflammatory compound tumor necrosis factor alpha (TNF-alpha) also rose significantly, notes Crandall.
The aim of the Celgene research was to create highly potent new drugs for down-regulating bodily production of tumor necrosis factor alpha, a hormone-like protein known to play a key role in inflammatory and immunological conditions of several serious disease states such as cachexia (the wasting in AIDS and cancer patients), rheumatoid arthritis, lupus, leprosy, inflammatory bowel disease and graft-versus- host disease.

Full browser ?